Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart M Flechner

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Nature Clinical Practice. Nephrology|February 28, 2008
Risk factors for and management of sirolimus-associated pneumonitis in kidney transplant recipientsStuart M Flechner
Transplant International : Official Journal of the European Society for Organ Transplantation|August 28, 2015
Optimizing immunosuppression: who can do more with less?Stuart M Flechner
Current Opinion in Organ Transplantation|March 18, 2026
Evaluation of nephrolithiasis and its risk factors in living kidney donor candidatesStuart M Flechner
Lancet (London, England)|February 22, 2011
Immunosuppression without calcineurin inhibition: by ZEUSStuart M Flechner
Transplantation|April 23, 2009
Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitorsStuart M Flechner
Urology|July 2, 2009
Editorial commentStuart M Flechner
Journal of the American Geriatrics Society|May 25, 2002
Will you still list me when I'm 64? Apologies to Lennon and McCartneyStuart M Flechner
Kidney International|April 1, 2011
Can the nephron be spared?Stuart M Flechner
Transplantation|February 24, 2017
mTOR Inhibition and Clinical Transplantation: KidneyStuart M Flechner
Urology|March 10, 2010
Re: Hajj et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure (Urology 2010;74:631-634)Stuart M Flechner
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Nature Clinical Practice. Nephrology|February 28, 2008
Risk factors for and management of sirolimus-associated pneumonitis in kidney transplant recipientsStuart M Flechner
Transplant International : Official Journal of the European Society for Organ Transplantation|August 28, 2015
Optimizing immunosuppression: who can do more with less?Stuart M Flechner
Current Opinion in Organ Transplantation|March 18, 2026
Evaluation of nephrolithiasis and its risk factors in living kidney donor candidatesStuart M Flechner
Lancet (London, England)|February 22, 2011
Immunosuppression without calcineurin inhibition: by ZEUSStuart M Flechner
Transplantation|April 23, 2009
Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitorsStuart M Flechner
Urology|July 2, 2009
Editorial commentStuart M Flechner
Journal of the American Geriatrics Society|May 25, 2002
Will you still list me when I'm 64? Apologies to Lennon and McCartneyStuart M Flechner
Kidney International|April 1, 2011
Can the nephron be spared?Stuart M Flechner
Transplantation|February 24, 2017
mTOR Inhibition and Clinical Transplantation: KidneyStuart M Flechner
Urology|March 10, 2010
Re: Hajj et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure (Urology 2010;74:631-634)Stuart M Flechner
Pageof 8